NEW YORK ( TheStreet) -- Amicus Therapeutics ( FOLD) has several phase II and phase III clinical trial catalysts over the next months that, if positive, could provide fuel for fairly large share-price appreciation on top of the 70% gains already seen in the stock year-to-date. Adam Feuerstein wrote a preview of the Amigal phase III monotherapy trial in Fabry disease last Friday. Options currently imply a $2.50 move in the shares -- $8.30 on the upside, $3.30 on the downside. An interesting, near-term, bullish trade with good risk reward is the following: Buy 100 JAN 5.0 strike Calls at 1.95 = $19,500 Sell 200 JAN 7.5 strike Calls at 1.10 = $(22,000) Buy 100 JAN 10.0 strike Calls at 0.50 = $5,000 Initial Trade P&L = $2,500 Debit This is a JAN expiration Call Butterfly (long.) Total risk is defined and equal to $2,500 and occurs if Amicus shares trades below $5 and above $10 by Jan. 19 expiration. The trade breaks even at $5.25 per share and $9.75 per share. Maximum return is $22,500 if Amicus shares hit $7.50 by expiration, which represents a risk/reward of 9 times. Pelz has no position in Amicus. To learn more about using options to trade biotech stocks, check out Tony Pelz's book, The Biotech Trader Handbook or subscribe to Chimera Research Group.